A tip of the hat to MGK for transcribing this.
Post# of 148151
(Total Views: 886)
Posted On: 12/10/2023 1:18:49 AM
Re: HouseofCards #139698
A tip of the hat to MGK for transcribing this.
You have someone in charge who runs trials so this time around there should be an appropriately sized trial. Which is absolutely essential to prove what leronlimab can do. The 24 week trial is almost certainly a phase 2 because this is new ground for leronlimab. If the endpoints are reductions in inflammatory markers it will be a slam dunk because we've already seen what leronlimab does.
The true benefit of this trial is that the FDA will have an better understanding (or should I say any understanding at all) of the widespread potential of leronlimab. This should make it much easier on Cytodyn in future trials for any other indication.
I've bemoaned the fact that basic research on the effects of leronlimab is lacking. Now it will be done.
Quote:
He said this endpoint is difficult to assess so I'm just curious if Ohm thinks this should be a slam dunk for us or if we're going to be biting our nails up until the results come out.
You have someone in charge who runs trials so this time around there should be an appropriately sized trial. Which is absolutely essential to prove what leronlimab can do. The 24 week trial is almost certainly a phase 2 because this is new ground for leronlimab. If the endpoints are reductions in inflammatory markers it will be a slam dunk because we've already seen what leronlimab does.
The true benefit of this trial is that the FDA will have an better understanding (or should I say any understanding at all) of the widespread potential of leronlimab. This should make it much easier on Cytodyn in future trials for any other indication.
I've bemoaned the fact that basic research on the effects of leronlimab is lacking. Now it will be done.
(18)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼